Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Abstract

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006, 171 of 344 patients…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60405-4

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Cited by

See all 2,154

Metadata

Authors
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., Valeyre, D., & du Bois, R. M.
Affiliations
  • Duke University (US)
  • University of Turin (IT)
  • Ruhrlandklinik (DE)
  • University of Miami (US)
  • University of California, San Francisco (US)
  • Vanderbilt University Medical Center (US)
  • Medical University of South Carolina (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Noble, Paul W
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-05
Volume
377
Issue
9779
Pages
1760-1769
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2057292199
Cited by
2,154
References
36
Citations by year
2026: 95 · 2025: 130 · 2024: 160 · 2023: 142 · 2022: 153 · 2021: 178 · 2020: 162 · 2019: 143 · 2018: 162 · 2017: 153 · 2016: 153 · 2015: 156 · 2014: 119 · 2013: 125 · 2012: 87
FWCI
97.97
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • BORIS (University Library Bern) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, lung function, anti-inflammatory agents, dose comparison, safety and tolerability, adverse events, drug discontinuation, pulmonary fibrosis progression, antifibrotic agents
MeSH terms
Administration, Oral, Aged, Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Disease-Free Survival, Kaplan-Meier Estimate, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(11)60405-4
The paper
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., Valeyre, D., & du Bois, R. M. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(11)60405-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.